JP2023541261A5 - - Google Patents
Info
- Publication number
- JP2023541261A5 JP2023541261A5 JP2023515808A JP2023515808A JP2023541261A5 JP 2023541261 A5 JP2023541261 A5 JP 2023541261A5 JP 2023515808 A JP2023515808 A JP 2023515808A JP 2023515808 A JP2023515808 A JP 2023515808A JP 2023541261 A5 JP2023541261 A5 JP 2023541261A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- pdeiv
- condition
- product according
- mediated disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026028686A JP2026102632A (ja) | 2020-09-10 | 2026-02-25 | Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076774P | 2020-09-10 | 2020-09-10 | |
| US63/076,774 | 2020-09-10 | ||
| PCT/US2021/049870 WO2022056265A1 (en) | 2020-09-10 | 2021-09-10 | Methods of treating pde iv-mediated diseases or conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026028686A Division JP2026102632A (ja) | 2020-09-10 | 2026-02-25 | Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541261A JP2023541261A (ja) | 2023-09-29 |
| JP2023541261A5 true JP2023541261A5 (enExample) | 2024-06-13 |
| JP7826294B2 JP7826294B2 (ja) | 2026-03-09 |
Family
ID=78080507
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023515808A Active JP7826294B2 (ja) | 2020-09-10 | 2021-09-10 | Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法 |
| JP2026028686A Pending JP2026102632A (ja) | 2020-09-10 | 2026-02-25 | Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026028686A Pending JP2026102632A (ja) | 2020-09-10 | 2026-02-25 | Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12622915B2 (enExample) |
| EP (1) | EP4210674A1 (enExample) |
| JP (2) | JP7826294B2 (enExample) |
| KR (1) | KR20230066350A (enExample) |
| CN (1) | CN116507336B (enExample) |
| AU (1) | AU2021338837A1 (enExample) |
| BR (1) | BR112023004214A2 (enExample) |
| CA (1) | CA3191177A1 (enExample) |
| CL (1) | CL2023000648A1 (enExample) |
| IL (1) | IL300628A (enExample) |
| MX (1) | MX2023002539A (enExample) |
| WO (1) | WO2022056265A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2025224045A1 (en) * | 2024-02-22 | 2026-08-06 | Vanda Pharmaceuticals, Inc. | Treatment of dry eye disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0314392A (pt) | 2002-09-16 | 2005-07-12 | Glaxo Group Ltd | Composto ou um sal do mesmo, composição farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de uma doença inflamatória e/ou alérgica ou deficiência cognitiva em um mamìfero, e, combinação |
| PL378245A1 (pl) | 2003-01-09 | 2006-03-20 | Astellas Pharma Inc. | Pochodne pirolopirydazyny |
| WO2007142929A2 (en) | 2006-05-31 | 2007-12-13 | The University Of North Carolina At Chapel Hill | Novel pde4 inhibitors |
| US8080563B2 (en) * | 2006-07-07 | 2011-12-20 | Kalypsys | Bicyclic heteroaryl inhibitors of PDE4 |
| ES2909316T3 (es) | 2015-12-24 | 2022-05-06 | Univ California | Reguladores de CFTR y métodos de uso de los mismos |
| KR20200044873A (ko) | 2017-08-24 | 2020-04-29 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 안구 제약학적 조성물 |
| TWI845795B (zh) * | 2019-12-05 | 2024-06-21 | 美商汎達製藥公司 | 眼用醫藥組合物 |
-
2021
- 2021-09-10 CN CN202180062221.XA patent/CN116507336B/zh active Active
- 2021-09-10 EP EP21787173.0A patent/EP4210674A1/en active Pending
- 2021-09-10 WO PCT/US2021/049870 patent/WO2022056265A1/en not_active Ceased
- 2021-09-10 JP JP2023515808A patent/JP7826294B2/ja active Active
- 2021-09-10 IL IL300628A patent/IL300628A/en unknown
- 2021-09-10 KR KR1020237008089A patent/KR20230066350A/ko active Pending
- 2021-09-10 BR BR112023004214A patent/BR112023004214A2/pt unknown
- 2021-09-10 CA CA3191177A patent/CA3191177A1/en active Pending
- 2021-09-10 US US18/044,805 patent/US12622915B2/en active Active
- 2021-09-10 AU AU2021338837A patent/AU2021338837A1/en active Pending
- 2021-09-10 MX MX2023002539A patent/MX2023002539A/es unknown
-
2023
- 2023-03-07 CL CL2023000648A patent/CL2023000648A1/es unknown
-
2026
- 2026-02-25 JP JP2026028686A patent/JP2026102632A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tsai | Role of interleukin 8 in depression and other psychiatric disorders | |
| DE69817393T2 (de) | Neue heterozyklische verbindungen | |
| KR102417080B1 (ko) | 신규한 노카르다민의 금속 착물 및 약제 조성물에서의 이의 용도 | |
| JP2009520697A5 (enExample) | ||
| US12043616B2 (en) | Crystalline forms of nicotinamide riboside chloride | |
| JP2019535761A5 (enExample) | ||
| JP2020526511A (ja) | ニコチンアミドリボシドの合成方法 | |
| JP2025510813A5 (enExample) | ||
| JPH09502170A (ja) | フェネチルアミン化合物 | |
| Wu et al. | Demethylase FTO promotes neuropathic pain development via regulating the m6A methylation levels of CXCR3 | |
| JP2021524507A (ja) | アレルギー疾患の治療方法 | |
| JP2022547080A5 (enExample) | ||
| DE60112768T2 (de) | Behandlung von entzündlichen erkrankungen | |
| JP7826294B2 (ja) | Ｐｄｅｉｖ媒介性の疾患又は状態を処置する方法 | |
| JP2022536279A5 (enExample) | ||
| WO2024050434A1 (en) | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR MEDIATED DISEASES | |
| CN118661691B (zh) | 一种过敏性鼻炎小鼠模型的构建方法 | |
| CN114306359A (zh) | 白头翁或其提取物的镇痛用途 | |
| JP2022551105A5 (enExample) | ||
| JP2008526945A5 (enExample) | ||
| CN120837512B (zh) | 一种抗焦虑的γ-氨基丁酸组合物及其制备方法 | |
| EP3600552A1 (en) | Compounds and compositions for use in treating psoriasis | |
| Marai | Case 3. Sustained benefits of ixekizumab treatment for long-standing psoriasis severely impacting quality of life | |
| WO2024050431A2 (en) | Tapinarof and analogs thereof for use in treating ahr mediated diseases | |
| CN118059116A (zh) | 利巴韦林在制备治疗过敏性鼻炎的药物中的应用 |